Threshold
BioCentury: Hypoxic Depth Charge
By WallStArb - Posted on May 31st, 2009
• Product Development - Hypoxic Depth Charge - Threshold Pharmaceuticals has preliminary Phase I/II data showing that its TH-302 hypoxia-activated prodrug (HAP) could kill cells in hypoxic regions of tumors where chemotherapy doesn't reach.
From BioCentury - http://www.biocentury.com
By Aaron Bouchie
Senior Writer
(1 vote)
